Abstract
Background
The earthworm fibrinolytic enzyme (EFE) is a complex protein enzyme that is widely distributed in the earthworm's digestive cavity. Possessing strong protein hydrolysis activity, EFE not only has a direct effect on fibrin, but also can activate plasminogen. Its therapeutic and preventative effects on thrombosis-related disease have been confirmed clinically. Recently, there has been increased interest in the anti-tumor activity of EFE. In this study, the anti-tumor activity of EFE, isolated from Eisenia foetida, on human hepatoma cells was evaluated in vitro and in vivo. The potential mechanisms involved were also studied.Methods
In vitro experiments were performed in four human hepatoma cell lines: HLE, Huh7, PLC/PRF/5 and HepG2. After treatment with EFE in various concentrations, the inhibition of the rate of cell proliferation was measured. For the in vivo studies, tumor-bearing models xenografted with Huh7 cells were developed in nude mice, and then the mice were fed with EFE once a day for 4 weeks, and the control group received only saline. An inhibitory effect on tumor growth was observed. Also, apoptosis was observed with flow cytometric assay and fluorescent dye staining with acridine orange and ethidium bromide (AO/EB). The expression of matrix metalloproteinase 2 (MMP-2) were detected by Western blotting assay.Results
After treatment with various concentrations of EFE, the proliferation of all hepatoma cell lines was suppressed to varying degrees in vitro. The IC(50) for HLE, Huh7, PLC/PCF/5 and HepG2 were 2.11, 5.87, 25.29 and 17.30 uku/ml, respectively. After administration of EFE orally for 4 weeks, the growth of tumor xenograft of Huh7 cells in nude mice was significantly inhibited in vivo. The tumor inhibitory rates in the EFE 500 uku/(kgxd) and 1000 uku/(kgxd) groups were 46.08% (compared with control group, P = 0.026) and 57.52% (compared with control group, P = 0.002) respectively. Meanwhile, the average weight of body, spleen or thymus did not show any remarkable differences among the various groups. The population in sub-G(1) stage was more in the EFE treated groups than in the control group according to flow cytometric assay. After treatment with EFE 0, 5, 10 uku/ml for 72 hours, the apoptotic rates were 3.5%, 10.9% and 12.3% in HLE cells, and 5.0%, 24.7% and 34.5% in Huh7 cells respectively. Under fluorescent staining with AO/EB, the apoptotic morphological changes could be detected more significantly in the EFE treated groups than in the untreated groups. After treatment with EFE in doses of 0, 5, 10 uku/ml for 72 hours, the apoptotic rates were 3.02%, 8.76%, 10.54% in HLE cells, and 3.95%, 18.27%, 30.89% in Huh7 cells respectively. The apoptosis-inducing effects of EFE occurred in a dose dependent manner. Western blotting assay showed that, after treatment with EFE, the secretions of MMP-2 were significantly inhibited in HLE and Huh7 cells.Conclusions
EFE showed significant anti-tumor activity in hepatoma cells both in vitro and in vivo, which may be because EFE could induce apoptosis of hepatoma cells and inhibit the expression of MMP-2. This suggests that EFE has a potential role in the treatment of hepatoma.Citations & impact
Impact metrics
Article citations
Purification and proteomic analysis of potent fibrinolytic enzymes extracted from Lumbricus rubellus.
Proteome Sci, 21(1):8, 08 May 2023
Cited by: 1 article | PMID: 37158880 | PMCID: PMC10165752
Bioactive Earthworm Peptides Produced by Novel Protease-Producing Bacillus velezensis PM 35 and Its Bioactivities on Liver Cancer Cell Death via Apoptosis, Antioxidant Activity, Protection Against Oxidative Stress, and Immune Cell Activation.
Front Microbiol, 13:892945, 10 Aug 2022
Cited by: 3 articles | PMID: 36033863 | PMCID: PMC9399677
Coelomic Fluid of Eisenia fetida Ameliorates Cetuximab to Reduce K-Ras and Vimentin Expression through Promoting RUNX3 in an AOM/DSS-Induced Colitis Associated Colon Cancer.
Evid Based Complement Alternat Med, 2020:9418520, 19 Jul 2020
Cited by: 2 articles | PMID: 32765634 | PMCID: PMC7387963
Anticancer Activity of Earthworm Powder (Lumbricus terrestris) Against MCF-7 and PC-3 Cancer Cell Lines.
J Gastrointest Cancer, 50(4):919-925, 01 Dec 2019
Cited by: 2 articles | PMID: 31321664
Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer.
Int J Nanomedicine, 13:3625-3640, 26 Jun 2018
Cited by: 5 articles | PMID: 29983558 | PMCID: PMC6027826
Go to all (32) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Chin Med J (Engl), 120(15):1336-1342, 01 Aug 2007
Cited by: 30 articles | PMID: 17711740
[Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Yao Xue Xue Bao, 43(8):811-818, 01 Aug 2008
Cited by: 0 articles | PMID: 18956773
[The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Zhonghua Yi Xue Za Zhi, 87(41):2919-2924, 01 Nov 2007
Cited by: 0 articles | PMID: 18261307
[A new strategy for the therapy of pancreatic cancer by proton pump inhibitor].
Gan To Kagaku Ryoho, 23(12):1660-1664, 01 Oct 1996
Cited by: 4 articles | PMID: 8886039
Review
Anticancer activity of polyoxomolybdate.
Biomed Pharmacother, 60(7):349-352, 30 Jun 2006
Cited by: 36 articles | PMID: 16860529
Review